These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 19712713

  • 1. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
    Hagenaars N, Verheul RJ, Mooren I, de Jong PH, Mastrobattista E, Glansbeek HL, Heldens JG, van den Bosch H, Hennink WE, Jiskoot W.
    J Control Release; 2009 Dec 03; 140(2):126-33. PubMed ID: 19712713
    [Abstract] [Full Text] [Related]

  • 2. A step-by-step approach to study the influence of N-acetylation on the adjuvanticity of N,N,N-trimethyl chitosan (TMC) in an intranasal nanoparticulate influenza virus vaccine.
    Verheul RJ, Hagenaars N, van Es T, van Gaal EV, de Jong PH, Bruijns S, Mastrobattista E, Slütter B, Que I, Heldens JG, van den Bosch H, Glansbeek HL, Hennink WE, Jiskoot W.
    Eur J Pharm Sci; 2012 Mar 12; 45(4):467-74. PubMed ID: 22009112
    [Abstract] [Full Text] [Related]

  • 3. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W.
    Vaccine; 2008 Dec 02; 26(51):6555-63. PubMed ID: 18848856
    [Abstract] [Full Text] [Related]

  • 4. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine.
    Hagenaars N, Mania M, de Jong P, Que I, Nieuwland R, Slütter B, Glansbeek H, Heldens J, van den Bosch H, Löwik C, Kaijzel E, Mastrobattista E, Jiskoot W.
    J Control Release; 2010 May 21; 144(1):17-24. PubMed ID: 20100528
    [Abstract] [Full Text] [Related]

  • 5. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJ, Jiskoot W.
    Vaccine; 2007 Jan 02; 25(1):144-53. PubMed ID: 16973248
    [Abstract] [Full Text] [Related]

  • 6. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
    Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A.
    Vaccine; 2008 May 02; 26(19):2350-9. PubMed ID: 18400340
    [Abstract] [Full Text] [Related]

  • 7. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO, Senel S.
    Int J Pharm; 2008 Nov 03; 363(1-2):139-48. PubMed ID: 18662762
    [Abstract] [Full Text] [Related]

  • 8. Physicochemical and immunological characterization of N,N,N-trimethyl chitosan-coated whole inactivated influenza virus vaccine for intranasal administration.
    Hagenaars N, Mastrobattista E, Verheul RJ, Mooren I, Glansbeek HL, Heldens JG, van den Bosch H, Jiskoot W.
    Pharm Res; 2009 Jun 03; 26(6):1353-64. PubMed ID: 19224344
    [Abstract] [Full Text] [Related]

  • 9. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
    Slütter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, Kaijzel E, van Eden W, Augustijns P, Löwik C, Bouwstra J, Broere F, Jiskoot W.
    Vaccine; 2010 Aug 31; 28(38):6282-91. PubMed ID: 20638455
    [Abstract] [Full Text] [Related]

  • 10. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
    Gupta NK, Tomar P, Sharma V, Dixit VK.
    Vaccine; 2011 Nov 08; 29(48):9026-37. PubMed ID: 21939718
    [Abstract] [Full Text] [Related]

  • 11. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.
    Vaccine; 2007 May 10; 25(19):3871-8. PubMed ID: 17337102
    [Abstract] [Full Text] [Related]

  • 12. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.
    Vaccine; 2006 May 01; 24(18):3990-4006. PubMed ID: 16516356
    [Abstract] [Full Text] [Related]

  • 13. Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration.
    Boonyo W, Junginger HE, Waranuch N, Polnok A, Pitaksuteepong T.
    J Control Release; 2007 Aug 28; 121(3):168-75. PubMed ID: 17644205
    [Abstract] [Full Text] [Related]

  • 14. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines.
    Ghendon Y, Markushin S, Krivtsov G, Akopova I.
    Arch Virol; 2008 Aug 28; 153(5):831-7. PubMed ID: 18297235
    [Abstract] [Full Text] [Related]

  • 15. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 16. The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination.
    Petersson P, Hedenskog M, Alves D, Brytting M, Schröder U, Linde A, Lundkvist A.
    Vaccine; 2010 Sep 07; 28(39):6491-7. PubMed ID: 20637767
    [Abstract] [Full Text] [Related]

  • 17. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?
    Slütter B, Bal SM, Que I, Kaijzel E, Löwik C, Bouwstra J, Jiskoot W.
    Mol Pharm; 2010 Dec 06; 7(6):2207-15. PubMed ID: 21043518
    [Abstract] [Full Text] [Related]

  • 18. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
    Sui Z, Chen Q, Fang F, Zheng M, Chen Z.
    Vaccine; 2010 Nov 10; 28(48):7690-8. PubMed ID: 20870054
    [Abstract] [Full Text] [Related]

  • 19. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model.
    Dabaghian M, Latifi AM, Tebianian M, NajmiNejad H, Ebrahimi SM.
    Vaccine; 2018 May 11; 36(20):2886-2895. PubMed ID: 29627234
    [Abstract] [Full Text] [Related]

  • 20. An α-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine.
    Lee YS, Lee KA, Lee JY, Kang MH, Song YC, Baek DJ, Kim S, Kang CY.
    Vaccine; 2011 Jan 10; 29(3):417-25. PubMed ID: 21087689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.